These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 37439495)

  • 1. Current Status of Weekly Insulin Analogs and Their Pharmacokinetic/Pharmacodynamic Evaluation by the Euglycemic Clamp Technique.
    An N; Wang X; He A; Chen W
    Clin Pharmacol Drug Dev; 2023 Sep; 12(9):849-855. PubMed ID: 37439495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biosynthetic Human Insulin and Insulin Analogs.
    Rodbard HW; Rodbard D
    Am J Ther; 2020; 27(1):e42-e51. PubMed ID: 31876563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice.
    Goldman J; Kapitza C; Pettus J; Heise T
    Curr Med Res Opin; 2017 Oct; 33(10):1821-1831. PubMed ID: 28537449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin degludec/insulin aspart in Japanese patients with type 1 diabetes mellitus: Distinct prandial and basal glucose-lowering effects.
    Haahr H; Sasaki T; Bardtrum L; Ikushima I
    J Diabetes Investig; 2016 Jul; 7(4):574-80. PubMed ID: 27181070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic and pharmacodynamic differences of new generation, longer-acting basal insulins: potential implications for clinical practice in type 2 diabetes.
    Hompesch M; Patel DK; LaSalle JR; Bolli GB
    Postgrad Med; 2019 Mar; 131(2):117-128. PubMed ID: 30691343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of basal insulins.
    Porcellati F; Bolli GB; Fanelli CG
    Diabetes Technol Ther; 2011 Jun; 13 Suppl 1():S15-24. PubMed ID: 21668333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Basal weekly insulins: the way of the future!
    Rosenstock J; Del Prato S
    Metabolism; 2022 Jan; 126():154924. PubMed ID: 34728221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin degludec/insulin aspart combination for the treatment of type 1 and type 2 diabetes.
    Dardano A; Bianchi C; Del Prato S; Miccoli R
    Vasc Health Risk Manag; 2014; 10():465-75. PubMed ID: 25143741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic and pharmacodynamic responses of insulin degludec in African American, white, and Hispanic/Latino patients with type 2 diabetes mellitus.
    Hompesch M; Morrow L; Watkins E; Roepstorff C; Thomsen HF; Haahr H
    Clin Ther; 2014 Apr; 36(4):507-15. PubMed ID: 24508419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine.
    Heise T; Hövelmann U; Nosek L; Hermanski L; Bøttcher SG; Haahr H
    Expert Opin Drug Metab Toxicol; 2015; 11(8):1193-201. PubMed ID: 26086190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Distinct Prandial and Basal Pharmacodynamics of IDegAsp Observed in Younger Adults Are Preserved in Elderly Subjects with Type 1 Diabetes.
    Brunner M; Pieber T; Korsatko S; Kojzar H; Svendsen AL; Haahr H
    Drugs Aging; 2015 Jul; 32(7):583-90. PubMed ID: 26088815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beyond the era of NPH insulin--long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application.
    Owens DR; Bolli GB
    Diabetes Technol Ther; 2008 Oct; 10(5):333-49. PubMed ID: 18715209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Newer insulin analogs: advances in basal insulin replacement.
    Zinman B
    Diabetes Obes Metab; 2013 Mar; 15 Suppl 1():6-10. PubMed ID: 23448197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of the new basal insulin analogs in addressing unmet clinical needs in people with type 1 and type 2 diabetes.
    Lajara R; Cengiz E; Tanenberg RJ
    Curr Med Res Opin; 2017 Jun; 33(6):1045-1055. PubMed ID: 28277867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Pharmacokinetics and Pharmacodynamics of Insulin Glargine 300 U/mL.
    Clements JN; Threatt T; Ward E; Shealy KM
    Clin Pharmacokinet; 2017 May; 56(5):449-458. PubMed ID: 27699623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early pharmacokinetic and pharmacodynamic effects of mixing lispro with glargine insulin: results of glucose clamp studies in youth with type 1 diabetes.
    Cengiz E; Tamborlane WV; Martin-Fredericksen M; Dziura J; Weinzimer SA
    Diabetes Care; 2010 May; 33(5):1009-12. PubMed ID: 20150302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [An update on multiple insulin injection therapy in type 1 and 2 diabetes].
    Varanauskiene E; Varanauskaite I; Ceponis J
    Medicina (Kaunas); 2006; 42(9):770-9. PubMed ID: 17028476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is insulin detemir able to favor a lower variability in the action of injected insulin in diabetic subjects?
    Valensi P; Cosson E
    Diabetes Metab; 2005 Sep; 31(4 Pt 2):4S34-4S39. PubMed ID: 16389896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin detemir (levemir), a new long-acting insulin.
    Med Lett Drugs Ther; 2006 Jul; 48(1238):54-5. PubMed ID: 16841022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Degludec: a novel basal insulin.
    Kalra S; Baruah MP; Niazi AK
    Recent Pat Endocr Metab Immune Drug Discov; 2012 Jan; 6(1):18-23. PubMed ID: 22280221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.